Report overview
Ovarian cancer occurs and arises from several types of cells within the ovary, and it has the lowest survival rate of all gynecological cancers. Among many types, epithelial ovarian cancer (EOC) is the most common ovarian cancer, whereas ovarian low malignant potential tumor (OLMPT), germ cell tumor, and stromal ovarian tumor are some of the less common types. It is the seventh most common cancer in women globally and 18th most common cancer overall. The ovarian cancer immunotherapies market has already got some commercially successful chemotherapy products. However, chemotherapy often involves a combination of two or more drugs, given intravenously every 3-4 weeks, and mostly associated with long-lasting side/adverse effects. Various studies have shown that chemotherapy can damage the blood-producing cells of the bone marrow, resulting in blood-related complications.
This report aims to provide a comprehensive presentation of the global market for Gene Therapy for Ovarian Cancer, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Gene Therapy for Ovarian Cancer. This report contains market size and forecasts of Gene Therapy for Ovarian Cancer in global, including the following market information:
Global Gene Therapy for Ovarian Cancer Market Revenue, 2018-2023, 2024-2029, ($ millions)
Global top five companies in 2022 (%)
The global Gene Therapy for Ovarian Cancer market was valued at US$ million in 2022 and is projected to reach US$ million by 2029, at a CAGR of % during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
Gene therapy is expected to be one of the next big paradigm shift in pharmacology due to the extensive on-going research studies, both at academic and industry level. Gene therapy is one of the most exciting approaches for the treatment of ovarian cancer. Replacement gene therapy is gaining attention as it has the potential to cure ovarian cancer and can be used as a promising option for long-lasting treatment.
We surveyed the Gene Therapy for Ovarian Cancer companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Gene Therapy for Ovarian Cancer Market, by Type, 2018-2023, 2024-2029 ($ millions)
Global Gene Therapy for Ovarian Cancer Market Segment Percentages, by Type, 2022 (%)
Intravenous
Intratumoral
Intraperitoneal
Global Gene Therapy for Ovarian Cancer Market, by Application, 2018-2023, 2024-2029 ($ millions)
Global Gene Therapy for Ovarian Cancer Market Segment Percentages, by Application, 2022 (%)
Ovarian Cancer (Unspecified)
Recurrent Ovarian Epithelial Cancer
Platinum-Resistant Ovarian Cancer
Global Gene Therapy for Ovarian Cancer Market, By Region and Country, 2018-2023, 2024-2029 ($ Millions)
Global Gene Therapy for Ovarian Cancer Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Gene Therapy for Ovarian Cancer revenues in global market, 2018-2023 (estimated), ($ millions)
Key companies Gene Therapy for Ovarian Cancer revenues share in global market, 2022 (%)
Further, the report presents profiles of competitors in the market, key players include:
Takara Bio
VBL Therapeutics
CELSION
Targovax
Outline of Major Chapters:
Chapter 1: Introduces the definition of Gene Therapy for Ovarian Cancer, market overview.
Chapter 2: Global Gene Therapy for Ovarian Cancer market size in revenue.
Chapter 3: Detailed analysis of Gene Therapy for Ovarian Cancer company competitive landscape, revenue and market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Gene Therapy for Ovarian Cancer in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: The main points and conclusions of the report.
